What are the causes and management of viral myocarditis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Viral myocarditis is primarily caused by viral infections, and its management should focus on supportive care, with hospitalization recommended for patients with definite myocarditis, ideally at an advanced heart failure center, as stated in the 2022 ACC Expert Consensus Decision Pathway 1. The most common viral causes of myocarditis include coxsackieviruses, adenoviruses, parvovirus B19, herpes viruses, and influenza viruses. Some key points to consider in the management of viral myocarditis include:

  • Restricting physical activity during the acute phase to reduce cardiac workload and prevent complications
  • Treatment with standard heart failure medications, such as ACE inhibitors, beta-blockers, and diuretics, if fluid retention is present
  • Avoiding nonsteroidal anti-inflammatory drugs, as they may worsen inflammation
  • Considering antiviral medications in specific cases, such as herpes virus infections
  • Regular cardiac follow-up with echocardiograms to monitor recovery According to the 2022 ACC Expert Consensus Decision Pathway, patients with myocarditis and COVID-19 pneumonia with an ongoing need for supplemental oxygen should be treated with corticosteroids 1. Additionally, the use of intravenous corticosteroids may be considered in patients with suspected or confirmed COVID-19 myocarditis with hemodynamic compromise or MIS-A, as this approach was associated with a favorable prognosis in a small series 1. Cardiovascular magnetic resonance (CMR) is also recommended in hemodynamically stable patients with suspected myocarditis, as it can noninvasively identify myocardial edema and provide a specific marker for acute inflammation, including its severity and localization 1. Overall, the management of viral myocarditis should prioritize supportive care, with a focus on reducing cardiac workload, preventing complications, and monitoring recovery, as outlined in the 2022 ACC Expert Consensus Decision Pathway 1.

From the Research

Causes of Viral Myocarditis

  • Viral infections are the most common cause of infectious myocarditis, with coxsackievirus B being a prevalent cause 2
  • Other viruses such as influenza A, COVID-19, human herpes virus 6, and parvovirus B19 can also cause myocarditis 3, 4, 5
  • The exact mechanism of viral-induced damage to myocytes is unknown, but likely involves immune-mediated and direct viral cytotoxicity 2
  • Myocarditis can occur secondary to direct cardiac invasion with the virus or to intense cytokine storm 3

Management of Viral Myocarditis

  • Treatment options include immunosuppressive agents, intravenous immunoglobulin (IVIG), antiviral agents, and natural products such as Astragalus membranaceus and Ardisia chinensis 2
  • Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and judicious use of beta-blockers are beneficial in management of myocarditis 3
  • Corticosteroids may be avoided during the early phase of viral replication, but can be beneficial in hospitalized, critically ill patients 3
  • Statins may be beneficial to shorten the course of the disease and decrease mortality 3
  • Milrinone and methylprednisolone have been used effectively in the treatment of SARS-CoV-2 related fulminant myocarditis 5

Diagnostic Tools

  • Elevated troponin, electrocardiogram, echocardiogram, and cardiac magnetic resonance are valuable tools to assist in diagnosis 3
  • Further diagnostic workup may be warranted in cases with multiple underlying active infections 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of viral myocarditis caused by coxsackievirus B.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.